Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Bone morphogenetic proteins and the polycystic ovary syndrome.

van Houten EL, Laven JS, Louwers YV, McLuskey A, Themmen AP, Visser JA.

J Ovarian Res. 2013 Apr 30;6(1):32. doi: 10.1186/1757-2215-6-32.

2.

The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.

Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A.

Hum Reprod. 2014 Apr;29(4):791-801. doi: 10.1093/humrep/det469. Epub 2014 Jan 16.

PMID:
24435776
3.

BMP system expression in GCs from polycystic ovary syndrome women and the in vitro effects of BMP4, BMP6, and BMP7 on GC steroidogenesis.

Khalaf M, Morera J, Bourret A, Reznik Y, Denoual C, Herlicoviez M, Mittre H, Benhaim A.

Eur J Endocrinol. 2013 Feb 20;168(3):437-44. doi: 10.1530/EJE-12-0891. Print 2013 Mar.

4.

Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.

Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H.

Acta Obstet Gynecol Scand. 2013 Dec;92(12):1369-74. doi: 10.1111/aogs.12247. Epub 2013 Oct 15.

PMID:
23980726
5.

The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.

Alebić MŠ, Stojanović N, Duhamel A, Dewailly D.

Hum Reprod. 2015 Aug;30(8):1927-33. doi: 10.1093/humrep/dev131. Epub 2015 Jun 4.

PMID:
26048913
6.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES).

Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC.

PMID:
26509855
7.

[Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].

Parahuleva N, Pehlivanov B, Orbecova M, Uchikova E, Ivancheva H.

Akush Ginekol (Sofiia). 2014;53(5):22-7. Bulgarian.

PMID:
25558667
8.

Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.

Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S.

Hum Reprod. 2011 Nov;26(11):3123-9. doi: 10.1093/humrep/der297. Epub 2011 Sep 16.

PMID:
21926054
9.

Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.

Pierre A, Peigné M, Grynberg M, Arouche N, Taieb J, Hesters L, Gonzalès J, Picard JY, Dewailly D, Fanchin R, Catteau-Jonard S, di Clemente N.

Hum Reprod. 2013 Mar;28(3):762-9. doi: 10.1093/humrep/des460. Epub 2013 Jan 14.

PMID:
23321213
10.

Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome.

Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):157-61. doi: 10.1016/j.ejogrb.2013.05.019. Epub 2013 Jun 24.

PMID:
23806449
11.

Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.

Pigny P, Jonard S, Robert Y, Dewailly D.

J Clin Endocrinol Metab. 2006 Mar;91(3):941-5. Epub 2005 Dec 20.

PMID:
16368745
12.

[Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].

Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E.

Akush Ginekol (Sofiia). 2013;52 Suppl 1:16-23. Bulgarian.

PMID:
24294740
13.

Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients.

Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, Natadisastra M, Hestiantoro A.

J Assist Reprod Genet. 2014 Oct;31(10):1311-6. doi: 10.1007/s10815-014-0300-6. Epub 2014 Aug 14.

14.

Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.

Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T.

Arch Gynecol Obstet. 2016 Feb;293(2):447-56. doi: 10.1007/s00404-015-3889-5. Epub 2015 Sep 25.

PMID:
26408006
15.

The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome.

Casadei L, Madrigale A, Puca F, Manicuti C, Emidi E, Piccione E, Dewailly D.

Gynecol Endocrinol. 2013 Jun;29(6):545-50. doi: 10.3109/09513590.2013.777415. Epub 2013 Mar 19.

PMID:
23506275
16.

The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study.

Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K.

Hum Reprod. 2013 Apr;28(4):1077-83. doi: 10.1093/humrep/det015. Epub 2013 Feb 1.

PMID:
23377771
18.

Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.

Dewailly D, Alebić MŠ, Duhamel A, Stojanović N.

Hum Reprod. 2014 Nov;29(11):2536-43. doi: 10.1093/humrep/deu242. Epub 2014 Sep 29.

PMID:
25267785
19.

Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries.

Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA.

Fertil Steril. 2012 Jul;98(1):242-9. doi: 10.1016/j.fertnstert.2012.03.059. Epub 2012 Apr 26. Erratum in: Fertil Steril. 2012 Sep;98(3):770.

20.

Supplemental Content

Support Center